Seek Returns

BIO.B vs. UTHR: Bio-Rad Laboratories vs. United Therapeutics Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while UTHR is classified in Biotechnology.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
Profile ItemBIO.BUTHR
NameBio-Rad Laboratories, Inc. Class B Common StockUnited Therapeutics Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.49 billion USD23.94 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999June 17, 1999
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
UTHR
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Total Return (1Y)27.69%28.77%
Total Return (3Y, Annualized)9.13%37.63%
Total Return (5Y, Annualized)-12.33%23.78%

Risk Profile

Drawdown History

BIO.B
UTHR
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Volatility (1Y, Annualized)30.96%35.00%
Beta (5Y)1.000.49
Max Drawdown (5Y)-70.74%-33.00%
Avg. Volume (3M)11694.55K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Sharpe Ratio (1Y)0.740.70
Sortino Ratio (1Y)1.101.29

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO.B) at 14.27% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max
109.18%
UTHR
19.13%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 39.45% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR
38.61%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max
83.12%
UTHR
28.99%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
ROE (TTM)14.27%19.13%
ROA (TTM)1.50%10.91%
Net Margin (TTM)39.45%38.61%
Operating Margin (TTM)9.46%28.99%
Gross Margin (TTM)52.19%86.34%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Revenue Growth (YoY)0.65%10.61%
Revenue Growth (3Y CAGR)-2.68%18.02%
EPS Growth (YoY)--13.07%
EPS Growth (3Y CAGR)--22.92%

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 3.18 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max
25.13
Q3
12.13
Median
5.52
UTHR
4.61
Q1
2.47
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Bio-Rad Laboratories (BIO.B) carries debt-to-equity ratio of 0.18 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
UTHR
--
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; BIO.B is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Current Ratio (MRQ)3.184.61
Debt / Equity (MRQ)0.18--
Net Debt / EBITDA-0.73-1.53

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while United Therapeutics (UTHR) at 21.22 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max
85.34
Q3
43.46
Median
26.69
UTHR
21.22
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max
58.18
Q3
25.77
UTHR
7.51
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while United Therapeutics (UTHR) at 3.80 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max
13.53
Q3
6.54
UTHR
3.80
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and United Therapeutics (UTHR)
MetricBIO.BUTHR
P/E Ratio (TTM)10.3621.22
P/S Ratio (TTM)4.057.51
P/B Ratio (MRQ)1.383.80
Free Cash Flow Yield (TTM)2.59%1.90%